Penis Drug Shown to Reduce Cellulite in Women
An exciting new announcement for women who suffer from unsightly cellulite has just been released by the biopharmaceutical company Auxilium, who reports that a penis drug to improve curvature of the penis has also been found to reduce cellulite in women.
The report originates from the results of a Phase 2a clinical trial that involved 150 women between the ages of 18 and 45 who each received up to three treatment sessions of drug or placebo. The study consisted of a randomized, double-blind protocol where test subjects were given either high-dose, mid dose, low dose injections of collagenase clostridium histolyticum (CCH) or a placebo injection to their individual cellulite affected regions - chiefly, the thighs and buttocks where significantly dimpling was present.
Cellulite is a common condition that affects millions of women in the U.S. and has been addressed in multiple episodes of The Dr. Oz Show where special cellulite fighting creams and anti-cellulite detox foods have been recommended.
According to the report, cellulite is a localized metabolic disorder of tissue under the skin that involves the loss of elasticity or shrinking of collagen cords, called "septae," that attach the skin to the muscle layers below. The result of loss of elasticity and/or shrinking of collagen cords allows accumulated fat to swell and expand around the septae resulting in the characteristic surface dimpling of cellulite.
Auxilium Pharmaceuticals, Inc. states that treatment with CCH―an approved drug in the U.S. for treating men with a penile curvature deformity of at least 30 degrees―works by targeting and breaking down the collagen tethers found in cellulite regions, which in turn releases the dimpled skin resulting in improved smoothening of the skin’s surface.
So how well did CCH perform in the study? The latest results demonstrated that of those who received mid to high doses of CCH, 68 percent of patients reported being "Satisfied" or "Very Satisfied" with the results of their treatment, compared to only 34 percent of randomized patients who were given placebo injections.
Satisfaction of results was calculated via a Global Aesthetic Improvement Scale (GAIS) that factored in both physician and patient assessments of individual results from the study treatments.